Literature DB >> 10399201

A Bayesian approach to modelling the natural history of a chronic condition from observations with intervention.

B A Craig1, D G Fryback, R Klein, B E Klein.   

Abstract

To assess the costs and benefits of screening and treatment strategies, it is important to know what would have happened had there been no intervention. In today's ethical climate, however, it is almost impossible to observe this directly and therefore must be inferred from observations with intervention. In this paper, we illustrate a Bayesian approach to this situation when the observations are at separated and unequally spaced time points and the time of intervention is interval censored. We develop a discrete-time Markov model which combines a non-homogeneous Markov chain, used to model the natural progression, with mechanisms that describe the possibility of both treatment intervention and death. We apply this approach to a subpopulation of the Wisconsin Epidemiologic Study of Diabetic Retinopathy, a population-based cohort study to investigate prevalence, incidence, and progression of diabetic retinopathy. In addition, posterior predictive distributions are discussed as a prognostic tool to assist researchers in evaluating costs and benefits of treatment protocols. While we focus this approach on diabetic retinopathy cohort data, we believe this methodology can have wide application.

Entities:  

Mesh:

Year:  1999        PMID: 10399201     DOI: 10.1002/(sici)1097-0258(19990615)18:11<1355::aid-sim130>3.0.co;2-k

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

Review 1.  The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.

Authors:  Grant H Skrepnek
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Modeling Disease Progression with Longitudinal Markers.

Authors:  Lurdes Y T Inoue; Ruth Etzioni; Christopher Morrell; Peter Müller
Journal:  J Am Stat Assoc       Date:  2008       Impact factor: 5.033

3.  Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules.

Authors:  Chad V Pecot; Ming Li; Xueqiong J Zhang; Rama Rajanbabu; Ciara Calitri; Aaron Bungum; James R Jett; Joe B Putnam; Carol Callaway-Lane; Steve Deppen; Eric L Grogan; David P Carbone; John A Worrell; Karel G M Moons; Yu Shyr; Pierre P Massion
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-28       Impact factor: 4.254

Review 4.  Dynamic microsimulation models for health outcomes: a review.

Authors:  Carolyn M Rutter; Alan M Zaslavsky; Eric J Feuer
Journal:  Med Decis Making       Date:  2010-05-18       Impact factor: 2.583

Review 5.  Bayesian methods for evidence synthesis in cost-effectiveness analysis.

Authors:  A E Ades; Mark Sculpher; Alex Sutton; Keith Abrams; Nicola Cooper; Nicky Welton; Guobing Lu
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Description and prediction of the development of metabolic syndrome: a longitudinal analysis using a markov model approach.

Authors:  Lee-Ching Hwang; Chyi-Huey Bai; San-Lin You; Chien-An Sun; Chien-Jen Chen
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.